Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bempikibart (Primary)
Indications Alopecia areata
Focus Proof of concept; Therapeutic Use
Acronyms SIGNAL-AA
Sponsors Q32 Bio

Most Recent Events

08 May 2025 According to a Q32 Bio media release, topline data readout on-track for the first half of 2026.
30 Apr 2025 According to a Q32 Bio media release, company announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to Q32 Bios bempikibart (ADX-914) for the treatment of Alopecia Areata.
20 Apr 2025 Planned number of patients changed from 44 to 75.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com